Bioasis Tech Stock Price, News & Analysis

Bioasis Technologies has filed its unaudited quarterly financial statements for the period ending May 31, 2022. The company focuses on developing its proprietary xB³™ platform technology aimed at delivering therapeutics across the blood-brain barrier, targeting CNS disorders with high unmet needs. Financial documents can be accessed through SEDAR and Bioasis's official website. The announcement was made by Deborah Rathjen, Executive Chair of the Board. Bioasis continues to advance its innovative approaches despite the inherent risks associated with drug development.

Bioasis Technologies has entered into an asset purchase agreement with Cresence AS to acquire Phase 2 ready assets for treating rare neurodegenerative diseases. The acquisition includes EGF1-48, which has proven safe in humans and targets conditions like Guillain-Barre Syndrome and multiple sclerosis. Bioasis aims to leverage its proprietary xB³ platform to enhance drug delivery across the blood-brain barrier. In exchange for these assets, Bioasis will issue up to 12.5 million shares and pay milestone royalties, subject to TSX Venture Exchange approval.

Bioasis Technologies has filed its audited annual financial statements for the period ending February 28, 2022. The company focuses on developing its xB³™ platform for delivering therapeutics across the blood-brain barrier to treat CNS disorders, including brain cancers and neurodegenerative diseases. These documents are available on SEDAR and Bioasis’s website. The press release highlights the importance of their platform in addressing critical health needs.

Bioasis Technologies Inc. (OTCQB: BIOAF) announced a research collaboration and license agreement with Neuramedy Co Ltd for the development of an xB^3TM version of Tomaralimab, aimed at treating neurodegenerative diseases like Parkinson's disease. Neuramedy will have worldwide rights to research, develop, and commercialize this antibody. Bioasis will receive an upfront payment, up to $72 million in milestone payments, and royalties on sales. This partnership aligns with Bioasis's strategy to expand its innovative drug delivery technology across the blood-brain barrier.

Bioasis Technologies Inc has announced a research collaboration with Janssen Biotech, Inc., part of Johnson & Johnson, to explore the potential of its proprietary xB3 platform technology for delivering therapeutics across the blood-brain barrier. This partnership could lead to the development of new treatments for brain disorders, addressing significant unmet clinical needs. Bioasis focuses on CNS disorders like Parkinson's disease and rare diseases including Gaucher’s Disease Type II, with the xB3 platform being central to their innovative approach.

BIOASIS TECHNOLOGIES INC (OTCQB:BIOAF) announced its participation in the Sachs 5th Annual Neuroscience Innovation Forum, where Dr. Deborah Rathjen, CEO, will present on advancements in Alzheimer's Disease and dementia. The event will occur digitally from March 21-25, 2022. Bioasis is focused on developing its proprietary xB3™ platform technology aimed at delivering therapeutics across the blood-brain barrier to tackle CNS disorders, including brain cancers and neurodegenerative diseases. This reflects Bioasis's commitment to addressing critical medical needs in the field.

Bioasis Technologies Inc. (OTCQB:BIOAF) has announced the completion of a non-brokered private placement, raising $200,000 from the issuance of 770,000 common shares at $0.26 per share. This funding aims to support Bioasis's development of its xB³™ platform technology, which focuses on therapeutic delivery across the blood-brain barrier for treating CNS disorders, including brain cancers and neurodegenerative diseases. The shares are subject to a four-month hold period under securities laws.

Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) announced the filing of its unaudited quarterly financial statements for the period ended November 30, 2021. The company focuses on developing its proprietary xB³™ platform technology aimed at delivering therapeutics across the blood-brain barrier, targeting CNS disorders, including brain cancers and neurodegenerative diseases. The financial documents are available on SEDAR and the company’s website, providing insights into its ongoing financial health and development strategies.

Bioasis Technologies (TSXV:BTI; OTCQB:BIOAF) announces the successful passing of all resolutions at its annual general meeting held on December 16, 2021, in New Haven, Connecticut. Shareholders re-elected five incumbent directors and approved Manning Elliott LLP as auditors for the next year. Bioasis is focused on developing its proprietary xB3™ platform technology for delivering therapeutics across the blood-brain barrier to treat CNS disorders including brain cancers and neurodegenerative diseases. The company continues to highlight its commitment to innovative treatments for unmet medical needs.